Mineralys Therapeutics had its Relative Strength (RS) Rating upgraded from 79 to 85 Tuesday.
Hone Your Stock-Picking Skills By Focusing On These Factors
This proprietary rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
History reveals that the best stocks typically have an RS Rating of over 80 in the early stages of their moves.
Mineralys Therapeutics is forming a consolidation with a 16.90 buy point. See if the stock can clear the breakout price in heavy trade.
The relative strength has entered new high ground, a sign the stock is outperforming the general market in terms of price performance.
The company showed 0% EPS growth last quarter. Revenue rose 0%.
Mineralys Therapeutics earns the No. 182 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
